腫瘤的增長(zhǎng)與擴(kuò)散依賴于新血管的生成或血管的新生。血管內(nèi)皮生長(zhǎng)因子受體（VEGFR）能促進(jìn)內(nèi)皮細(xì)胞的增殖，增強(qiáng)血管的滲透性，是控制新生血管生成的重要調(diào)控因子之一。Tivozanib是一種新型高選擇抑制VEGFR的喹唑啉脲類化合物，體內(nèi)外實(shí)驗(yàn)表明本品具有顯著的抗血管生成和抑制抗腫瘤生長(zhǎng)的活性，目前對(duì)腎細(xì)胞癌的治療正在進(jìn)行Ⅲ期臨床實(shí)驗(yàn)。

The sustained growth and dissemination of tumors are dependent on the process of new vessel formation or angiogenesis. Vascular endothelial growth factor receptors (VEGFR) which is one of important regulatory factors could promote the proliferation and survival of endothelial cells, increase the vascular permeability, and control the generation of new blood vessels. Tivozanib is a novel oral quinoline urea derivative that is a highly potent and selective VEGFR. The compound has demonstrated antiangiogenic and antitumor activities in vitro and in vivo and is an ongoing phase Ⅲ registration trial in renal cell carcinoma.